What question did this study set out to answer?

To assess the antileukemic activity and immunomodulatory effects of recombinant interleukin-2 in patients across various stages of chronic myelogenous leukemia.

March 1, 1999Journal of Immunotherapy

Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients

View Full Paper

Ask AI

Bookmark

To assess the antileukemic activity and immunomodulatory effects of recombinant interleukin-2 in patients across various stages of chronic myelogenous leukemia.
Enrolled 21 patients with chronic myelogenous leukemia, including 11 in chronic phase (6 in hematologic remission, 5 with active disease), 6 in accelerated phase, and 4 in blastic phase.
Administered recombinant interleukin-2 via intravenous bolus infusions at 8 × 10^6 IU/m^2 across three 5-day cycles given every other week, evaluating response at day 45.
No hematologic responses occurred in patients with active leukemia; among patients in remission, one achieved a major cytogenetic response (Philadelphia-positive metaphases decreased from 72% to 9%) and two showed partial reductions.
All cytogenetic responses were brief (< 6 months), though two patients subsequently attained a cytogenetic response after switching to interferon therapy.
Treatment produced substantial immune stimulation, including marked increases in CD3+/CD25+ cells, CD56+ cells, and natural killer/lymphokine-activated killer cell cytotoxicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase II trial reveals transient immune activation and limited cytogenetic response with interleukin-2 in chronic myelogenous leukemia, suggesting utility is restricted to low disease burden.

Cite This Study

Vey et al. (1999) studied this question.

synapsesocial.com/papers/6a1ed5986c8710472f7e849e https://doi.org/10.1097/00002371-199903000-00009

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial reveals transient immune activation and limited cytogenetic response with interleukin-2 in chronic myelogenous leukemia, suggesting utility is restricted to low disease burden.

Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients

Key Points

Discussion

Implication

Cite This Study

Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider